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A defective permeability barrier leads to the penetration of environmental allergens into the skin and initiates
immunological reactions and inﬂammation crucially involved in the pathogenesis of atopic dermatitis (AD).
Decreased stratum corneum ceramide content may cause the defect in permeability barrier function consistently
found in AD. Acid and neutral sphingomyelinase (A- and N-SMase) generate ceramides with structural and signal
transduction functions in epidermal proliferation and differentiation. We determined epidermal SMase activities,
DNA synthesis, involucrin, loricrin, ﬁlaggrin, and keratin expression in lesional and non-lesional skin of AD
patients. We found decreased epidermal A-SMase activity in lesional and non-lesional skin, correlating with
reduced stratum corneum ceramide content and disturbed barrier function. N-SMase activity was reduced in non-
lesional skin and more signiﬁcantly reduced in lesional skin, correlating with impaired expression of corniﬁed
envelope proteins and keratins, important for skin barrier function. Changes in involucrin, loricrin, ﬁlaggrin, keratin
K 5 (basal) and K 16 (proliferation associated) were noticed in non-lesional and lesional skin, whereas changes in K
10 (suprabasal), K 6 (proliferation associated), and K 17 (inﬂammation associated) were found only in lesional skin.
In summary, reduction in SMase-generating ceramides and impaired differentiation are involved in the defective
barrier function found in AD.
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The stratum corneum, the main permeability barrier, is
formed from extracellular lipids and corneocytes during
epidermal differentiation of the skin (Elias and Menon, 1991;
Lee et al, 1992; Mauro et al, 1998a, b). Epidermal lipids are
synthesized by keratinocytes and stored in epidermal
lamellar bodies, which contain cholesterol, phospholipids,
glucosylceramides, and hydrolytic enzymes including b-
glucocerebrosidase and acid sphingomyelinase (A-SMase).
The hydrolytic enzymes are delivered to stratum corneum
interstices where they convert secreted glucosylceramides
and phospholipids, including sphingomyelin, into ceramides
and free fatty acids (Schu¨rer and Elias, 1991). Ceramides,
due to their amphiphilic structure and extremely long-chain,
constituent N-acyl fatty acids, are essential for barrier
function. In keratinocytes, TNF rapidly activates two dis-
tinct types of SMases, the endosomal A-SMase and a
cell membrane-associated neutral sphingomyelinase (N-
SMase) (Wiegmann et al, 1994). The subcellular site of
production apparently determines the mode of action of
ceramides. We and others have recently shown that A-
SMase plays a major role in ceramide generation for
epidermal barrier function (Jensen et al, 1999, Schmuth
et al, 2000). Epidermal sphingomyelins of different structures
are precursors for two of the seven known stratum corneum
ceramides, ceramides 2 and 5. Ceramide 2 is quantitatively
the most important ceramide in the epidermis and ceramide
5 is probably exclusively obtained by sphingomyelin
hydrolysis (Robson et al, 1994; Vicanova et al, 1998; Uchida
et al, 2000). Beyond their structural importance, SMase-
produced ceramides have been recognized as an important
second messenger in intracellular signaling of various
cytokines and growth factors, depending on cell type.
Epidermal ceramides are obtained by a synthetic path-
way (Holleran et al, 1991a, b) and through hydrolysis from
glucosylceramide (Holleran et al, 1993, 1994) and sphingo-
myelin during a step regulated by the enzyme A-SMase
(Bowser and Gray, 1978). Atopic dermatitis (AD) samples
displayed a decrease in total lipids, sterol esters, and
phospholipids including sphingomyelin, as well as an
increase in free fatty acids and sterols compared with
normal controls (Mustakallio et al, 1967; Jakobza et al,
1981; Barth et al, 1989; Scha¨fer and Kragballe, 1991). Also,
AD samples showed a significant decrease in ceramide
content and all ceramide subfractions (Melnik et al, 1988,
1989a and b; Imokawa et al, 1991, Yamamoto et al, 1991).
Ceramide content in the stratum corneum correlated with
barrier function in AD (Di Nardo et al, 1998).
Epidermal proliferation and differentiation are also very
important for permeability barrier formation in the stratum
corneum (Ekanayake-Mudiyanselage et al, 1998; Marekov
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and Steinert, 1998). Keratinocytes synthesize specific basal
(K 5 and K 14) and suprabasal (K 1 and K 10) keratins, as
well as cornified envelope associated proteins, in particular
involucrin and loricrin (Fuchs and Green, 1980; Cline and
Rice, 1983; Watt, 1983; Moll et al, 1984; Wertz et al, 1989;
Mehrel et al, 1990; Hohl, 1993; Ekanayake-Mudiyanselage
et al, 1998).
During cornification, the phospholipid-enriched plasma
membrane is replaced by a ceramide-containing membrane
bilayer, which attaches covalently to involucrin, envoplakin,
and periplakin moieties on the extracellular surface of the
cornified envelope by o-hydroxyester bonds (Marekov
and Steinert, 1998). Transepidermal water loss (TEWL, as
marker for skin permeability barrier function) levels correlate
to the content of covalently bound ceramides (Meguro et al,
2000). Levels of covalently bound ceramides have recently
been determined in AD. Protein-bound o-hydroxycera-
mides represent 50% of protein-bound lipids in healthy
skin, but significantly less in non-lesional and lesional skin
(Macheleit et al, 2002).
Although defective skin permeability barrier function is an
accepted element of AD, abnormality of the epidermis is
regarded as a consequence of inflammation (Bos et al,
1994). Even in the asymptomatic skin of atopics, however,
disturbance of epidermal barrier function through scratch-
ing promotes penetration of antigens as well as eczematous
dermatitis (Ogawa and Yoshiike, 1993). Lifestyle modifica-
tions such as excessive use of detergents and shampoos
remove skin lipids and irritate the skin (McNally et al, 1998).
Finally, psychological stress has been shown to increase
skin irritability and abnormal barrier function. (Elias et al,
1997, 1999; Altemus et al, 2001; Garg et al, 2001). Atopic
patients, however, display abnormal barrier function in
both symptomatic and asymptomatic skin, leading to the
assumption that a barrier-initiated cytokine cascade main-
tains the homeostasis of the skin barrier (Wood et al, 1992,
1996; Gfesser et al, 1996).
Disturbances in barrier function enable aeroallergens
to penetrate the skin more easily, perpetuating the cycle
of eczematous lesions (Ghadially et al, 1992). Additional
studies have shown a 2–5-fold increase in basal TEWL in
non-lesional skin in AD (Yoshiike et al, 1993). In contrast,
TEWL levels and stratum corneum water content became
normal in patients free from AD symptoms for more than 5 y
(Matsumoto et al, 2000).
AD patients showed a thinner horny layer as well as a
reduced mean corneocyte area in different types of clinically
asymptomatic skin (Al-Jaberi and Marks, 1984). Only AD
patients showed an increased sensitivity to chemical
irritants and increased epidermal thickness (Nassif et al,
1994). In forced desquamation, atopic patients released
more corneocyte clumps from the epidermis than controls
(Watanabe et al, 1991). These results suggest that, in
addition to the known changes in lipid content, changes in
epidermal differentiation may occur in AD.
In this study, we found a decrease in the activities of
ceramide-generating SMases important for structural func-
tion and lipid signaling. SMases may not only generate
ceramides for structural function in the stratum corneum
lipid bilayers but are involved in the regulation of prolifera-
tion and differentiation in AD.
Results
Patients with AD showed changes in TEWL and stratum
corneum hydration To examine whether our patients
exhibited changes in barrier function and skin hydration,
we determined TEWL and stratum corneum conductance
by biophysical methods (Pinnagoda et al, 1990; Hashimoto-
Kumasaka et al, 1993). TEWL was 2-fold increased in non-
lesional and 4-fold increased in lesional skin of patients with
AD compared with the skin of normal controls (po0.05,
n¼8, respectively) (Fig 1A). Hydration was significantly
reduced in non-lesional (24.5%) as well as lesional
(39.1%) epidermis of AD compared with controls (both
po0.005, n¼8) (Fig 1B).
A- and N-SMase are reduced in AD In several previous
publications, a reduced or changed ceramide content in the
stratum corneum has been described (Melnik et al, 1988,
1989; Melnik and Plewig, 1989; Imokawa et al, 1991;
Yamamoto et al, 1991; Di Nardo et al, 1998), but the
mechanisms leading to this disturbance are largely un-
known. Therefore, we examined whether SMase activity,
which releases ceramides through sphingomyelin-hydro-
lysis, is impaired in AD. We directly assayed enzyme acti-
vity in epidermal samples obtained from lesional and
non-lesional skin in AD and in healthy controls. In healthy
skin, the activity of A-SMase was approximately 4.2 nmol
per h per mg protein, while the activity of N-SMase was
approximately 1.7 nmol per h per mg. Both A- and N-SMase
showed reduced levels of activity in AD. A-SMase showed
63% reduction in non-lesional and 48% reduction in lesional
epidermis, corresponding to 2.6 nmol per h per mg and
2.0 nmol per h per mg, respectively (both po0.05, n¼6)
in patients with AD compared with the skin of healthy
volunteers (Fig 2A). N-SMase activity was reduced by
50% in non-lesional skin and by 70% in lesional skin,
corresponding to 0.85 nmol per h per mg and 1.20 nmol per
h per mg, respectively (both: po0.05, n¼ 5) (Fig 2B). These
Figure1
Reduced barrier function and skin hydration in AD. TEWL and skin
hydration were measured in lesional and non-lesional skin of patients
with AD and in healthy controls, using a Tewameter TM210 and
Corneometer. TEWL (A) was increased in non-lesional and lesional skin
of patients with AD compared to the skin of normal controls (po0.05,
n¼ 8, respectively). Hydration (B) was significantly reduced in non-
lesional as well as lesional epidermis of AD compared with controls
(both po0.005, n¼ 8).
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results suggest that a disturbed hydrolysis of epidermal
sphingomyelin may account for the reduced ceramide
levels in AD.
In vitro A-SMase assays has a 94% speciﬁcity for
A-SMase Since not only A-SMase, but also the recently
described sphingomyelin deacylase uses the same sub-
strate (sphingomyelin) to produce lyso-sphingomyelin,
we had to verify that measuring the liberation of [14C]-
phosphorylcholine in the aqueous phase of the in vitro
assays using N-methyl [14C]-sphingomyelin as substrate is
not contaminated with [14C]-lyso-sphingomyelin derived
from sphingomyelin deacylase activity. For this, we assayed
purified A-SMase and purified sphingomyelin deacylase at
conditions optimal for A-SMase in the presence of EDTA
and optimal for sphingomyelin deacylase with Ca2þ instead
of EDTA. As depicted in Fig 3A, Ca2þ only slightly reduced
the production of phosphorylcholine derived from A-SMase
activity, while the production of lyso-sphingomyelin by
sphingomyelin deacylase was strictly dependent on Ca2þ .
Since the assays used before to determine A-SMase in the
skin biopsies contained EDTA and no CaCl2, a cross-activity
of sphingomyelin deacylase in the assay appears unlikely.
We repeated the assays using skin biopsies from healthy
controls, and as shown in Fig 3B, in the presence of Ca2þ
only lyso-sphingomyelin is detected, while in the absence of
Ca2þ and presence of EDTA, the prominent band corre-
sponds to phosphorylcholine and only a minor band (less
than 6% of the total radioactivity) occurred at the position of
lyso-sphingomyelin. Thus, measuring radioactivity by scin-
tillation counting of the aqueous phase of the in vitro
A-SMase assays is specific for A-SMase at least by 94%.
Increased proliferation in epidermal samples of patients
with AD We have previously shown that epidermal DNA
synthesis, a marker for proliferation, increases during
permeability barrier repair after experimental barrier disrup-
tion (Proksch et al, 1991). In this study using the Ki-67
marker, we found that lesional skin exhibited 5-fold higher
amounts of labeled cell nuclei in the basal and the lower
spinous layers (Fig 4). Even in non-lesional skin epidermis,
however, the number of labeled cells was significantly
increased (2-fold increased compared with controls). This
demonstrates increased proliferation in non-lesional and
more pronounced in lesional skin of AD.
Altered distribution of involucrin, loricrin, ﬁlaggrin,
and keratins in the epidermis Immunohistochemistry with
several differentiation-associated proteins is shown in
Fig 4. In healthy epidermis during normal differentiation,
involucrin is expressed only in the upper spinous layers and
the stratum granulosum. In non-lesional atopic skin, the
band of involucrin staining broadened and was already
found in the middle part of the spinous layers. In lesional
atopic skin, we found premature expression of involucrin
already in the lower spinous layers. The intensity of the
staining reduced, however, with dark brown staining
appearing in healthy control skin and light brown staining
in diseased skin.
The amount of loricrin was enhanced in non-lesional as
well as in lesional atopic skin. Whereas loricrin staining in
healthy skin was limited to the upper stratum granulosum,
staining appeared in the entire granular cell layer of
non-lesional skin. Loricrin staining extended to the upper
spinous layers in an uneven pattern in lesional skin. The
Figure 2
Reduced A- and N-SMase activities in AD. The enzymatic activities
of A-SMase and N-SMase were determined after extraction from punch
biopsies by mixed micellar in vitro assays using [14C] sphingomyelin as
substrate. A-SMase (A) showed a significant reduction in lesional and
non-lesional skin in patients with AD compared with the skin of healthy
volunteers (both po0.05, n¼ 6). Also, N-SMase (B) activity was
reduced in non-lesional and in lesional skin (both po0.05, n¼ 5).
Figure3
Determination of A-SMase and sphingomyelin deacylase activity
depending on Ca2þ . As not only the ceramide-generating A-SMase,
but also sphingomyelin deacylase uses sphingomyelin as substrate to
produce lyso-sphingomyelin, we needed to verify that measurements
of the liberation of [14C]-phosphorylcholine in the aqueous phase of the
in vitro assays using [14C]-N-methyl sphingomyelin as substrate were
not contaminated with [14C]-lyso-sphingomyelin derived from sphingo-
myelin deacylase activity. Exogenous A-SMase and sphingomyelin
deacylase were assayed in either buffer D containing EDTA or in buffer
E, containing CaCl2. As depicted in (A), Ca
2þ only slightly reduced the
production of phosphorylcholine derived from A-SMase (left two blots),
whereas the production of lyso-sphingomyelin by sphingomyelin
deacylase (right two blots) was strictly dependent on Ca2þ . Using
skin biopsies from healthy controls in the presence of Ca2þ only lyso-
sphingomyelin is detected, whereas in the absence of Ca2þ and
presence of EDTA, the prominent band corresponds to phosphorylcho-
line and only a minor band (less than 6% of the total radioactivity)
occurred at the position of lyso-sphingomyelin (B).
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thickness of the stained layers increased 2-fold as com-
pared with non-lesional skin.
In healthy and in non-lesional skin, filaggrin is primarily
expressed in the granular and the transition zone to the
lower horny layers of the skin. The filaggrin staining appears
thinned in non-lesional skin. In lesional skin, the thickness of
the stained band increased 5-fold. This was primarily due to
increased thickness of the granular layer in concert with an
overall increase of epidermal thickness, but filaggrin does
not reach the horny layers in lesional epidermis and stains
primarily to the granules in the stratum granulosum cells.
Remarkably, staining intensity for filaggrin in non-lesional
and lesional skin of AD was significantly reduced.
Immunostaining for basal K 5 was primarily restricted to
the basal epidermal layer in healthy skin. In non-lesional
skin, extension to suprabasal epidermal layers occurred, but
staining intensity remained most pronounced in the basal
layer. In lesional atopic skin, we found equal distribution of K
5 throughout the entire nucleated epidermal layers.
Proliferation-associated K 6 was not expressed in
healthy control skin or in non-lesional AD skin. In contrast,
pronounced staining in the suprabasal layers appeared in
lesional AD skin.
Suprabasal/differentiation-related K 10 expression was
found in the entire suprabasal compartment in healthy
control and in non-lesional AD skin. In lesional AD, staining
for K 10 was concentrated in the granular and upper
spinous layers, but reduced in the lower spinous layers of
the epidermis.
The proliferation-associated cytokeratin K 16 was not
expressed in healthy skin. In non-lesional skin, intense
staining was already noticeable in the middle and upper
parts of the spinous layers. In lesional AD, intense staining
occurred in all the suprabasal layers.
The inflammation-associated K 17 was not expressed in
healthy skin or in non-lesional skin. In lesional skin, staining
was found in all suprabasal layers with continually increas-
ing intensity toward the stratum granulosum.
Quantitative analysis of involucrin and loricrin as
markers of terminal differentiation using western blot-
ting Using immunoblotting analysis, we demonstrated that
extracts of epidermal proteins contain involucrin as well as
loricrin, both in the lesional and non-lesional skin of patients
with AD and healthy volunteers. We found reduced levels of
mature involucrin (65 kDa) in non-lesional skin (35%, NS,
Figure4
Impaired epidermal proliferation and differentiation in non-lesional
and lesional skin of patients with AD as shown by immunohis-
tochemistry. Increased labeling of proliferating keratinocytes is seen
in non-lesional and more pronounced in lesional epidermis (Ki-67
antibody staining). Premature expression of involucrin was found in
non-lesional and more pronounced in lesional skin. Staining intensity,
however, was reduced. The loricrin staining band broadened in lesional
skin and broadened more in non-lesional AD. Basal K 5 expression was
restricted to the basal layer in normal skin, but extended to the stratum
spinosum in non-lesional and even to the entire nucleated epidermis in
lesional AD. K 6, known to be proliferation associated, appeared
in lesional AD epidermis. The expression of differentiation related/
suprabasal K 10 was found in the entire suprabasal epidermis in normal
and in non-lesional skin of AD, but staining was reduced in diseased
skin. K 16 labeling was already found in non-lesional skin and more
pronounced in lesional skin of AD, whereas K 17 showed immunostain-
ing only in lesional epidermis.
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the differences did not reach significance due to the small
sample size of human biopsies, n¼ 6) and even more
reduced levels in lesional epidermis (52%, po0.05, n¼ 6)
of AD (Fig 5A).
With immunohistochemistry, the broadening of the
stained band with unchanged intensity already suggested
an increase in the total amount of loricrin. In western blot
analysis, loricrin levels showed a 3-fold increase in non-
lesional (þ233%, po0.01, n¼ 6), and lesional epidermis
(þ 341%, po0.01, n¼6) compared with control samples
(Fig 5B).
Discussion
In this study, we found a significant reduction of A-SMase
activity in lesional as well as in non-lesional epidermal
samples from patients with AD compared with normal
controls. The reduced A-SMase activity is most probably
responsible in part for the reduced stratum corneum
ceramide content, which manifests in AD (Melnik et al,
1988, 1989; Melnik and Plewig, 1989; Imokawa et al, 1991;
Yamamoto et al, 1991; Di Nardo et al, 1998). Previously, A-
SMase protein immunostaining extending from the upper
spinous cell layers to the upper stratum corneum and a
slight increase in lesional versus non-lesional stratum
corneum in AD has been described (Kusuda et al, 1998).
The immunostaining result does not necessarily contradict
our findings, as it shows the localization and content of
the protein, but not the level of activity of the enzyme.
In contrast, we directly measured A-SMase activity with a
specific in vitro enzyme assay. Our results correlate reduced
A-SMase activity with reduced ceramide content in AD.
Recently, it was found that the AD epidermis contains
elevated levels of a new enzyme glucosylceramide/sphin-
gomyelin deacylase, which cleaves the N-acyl linkage of
both sphingomyelins and glucosylceramides. It was
claimed that this may be the cause of the reduced ceramide
content in AD, because sphingomyelin deacylase reduces
ceramides by releasing free fatty acids and sphingo-
syl-phosphorylcholine (Murata et al, 1996; Hara et al,
2000; Higuchi et al, 2000; Imokawa, 2001). Sphingomyelin
deacylase uses the same substrate sphingomyelin as
A-SMase, but in contrast to A-SMase, its activity strictly
depends on Ca2þ . Since our in-vitro A-SMase assays
contain EDTA instead of CaCl2, we can exclude enzymatic
activity of sphingomyelin deacylase (Fig 3A). In the skin
biopsies we found a residual amount of radiolabeled lyso-
sphingomyelin of less than 6% (Fig 3B). The activity of acid
sphingomyelin deacylase was reportedly enhanced in
atopic skin (Hara et al, 2000), and we measured a strong
reduction in A-SMase activity, indicating that the two assays
indeed measure both enzymes independently. Our data
show that SMases (which are downregulated in AD) do not
contribute to the reduced sphingomyelin levels. Given the
possibility that sphingomyelin deacylase and SMases
compete for the same substrate, the high sphingomyelin
deacylase activity resulting in reduced sphingomyelin levels
may even be a reason for the downregulated SMases
observed in our study. The decreased SMases shown in
our report will, in concert with enhanced sphingomyelin
deacylase activity, further reduce the availability of cera-
mides in the stratum corneum of atopic skin.
Jin et al examined b-glucocerebrosidase and cerami-
dase activities in the stratum corneum of AD and age-
related dry skin. As they did not find differences in either
b-glucocerebrosidase or ceramidase activities in uninvolved
stratum corneum of AD, the decrease of ceramides in AD
could not be attributed to enhanced ceramide degradation
(Jin et al, 1994). Likewise, the presence of unchanged
b-glucocerebrosidase in stratum corneum from non-ecze-
matous dry skin of AD was confirmed by Redoules
(Redoules et al, 1999; reviewed in Proksch et al, 2003).
We found that N-SMase activity was also reduced, but
based on the comparatively lower activity of this enzyme to
A-SMase, the contribution of A-SMase appears to be more
important. The role of N-SMase in the skin is only partially
known. It has been described that stress-induced changes
in the immune system and in keratinocyte cell growth are
mediated by the SMase signal transduction pathway
leading to changes in membrane-bound N-SMase activity
(Buisson-Legendre et al, 1999; Korneva et al, 2001). Clinical
evidence confirms stress-induced aggravation of AD. These
changes correlate to our results of impaired N-SMase
activity and epidermal differentiation.
We found a several-fold increase in epidermal prolifera-
tion in AD after staining with Ki-67 antibody. Similar results
have been previously described after in vitro incorporation
with tritiated thymidine (Van Neste et al, 1979). Increased
proliferation may be an attempt to reconstitute normal
barrier function and to remove invaded antigens. We have
previously shown that epidermal DNA synthesis increases
during permeability barrier repair after experimental skin
injury (Proksch et al, 1991). Here we show that epidermal
proliferation is already increased in uninvolved AD skin. An
increase in epidermal proliferation was found previously in
young and aged dry skin (Engelke et al, 1997). AD skin
is well known for dry skin conditions; reduced stratum
corneum hydration was also noted in our patients. The
Figure5
Reduced involucrin and increased loricrin in AD as shown by
western blotting. Epidermal proteins from punch biopsies were
extracted and analyzed by western blotting. Specific bands for
involucrin (A) and loricrin (B) were identified with immunostaining and
quantified by 2D laser scanning densitometry and given in arbitrary
units. Involucrin levels decreased, whereas loricrin levels increased
significantly in lesional and non-lesional skin of AD (involucrin: non-
lesional NS, n¼6, the differences did not reach significance due to the
small sample size of human biopsies, lesional po0.01, n¼ 6, loricrin:
po0.01, n¼6).
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increase in epidermal proliferation may also be related to
dry skin in AD.
Increased epidermal proliferation is often linked to
disturbed differentiation, as there may not be sufficient time
for proper differentiation during exaggerated epidermal
proliferation. Epidermal differentiation is of crucial impor-
tance for the integrity of the permeability barrier (Eka-
nayake-Mudiyanselage et al, 1998). As filaggrin expression
is linked to stratum corneum hydration and filaggrin content
is reduced in atopic skin, it has been suggested that
frequently seen skin dryness in atopic patients may derive
from these filaggrin changes (Scott and Harding, 1986).
A decreased staining for involucrin and filaggrin has
been described previously in non-lesional skin of AD and
decreased filaggrin was confirmed by the ELISA method
(Seguchi et al, 1996). In our studies, total staining density of
involucrin and filaggrin were reduced, thereby suggesting
a reduced protein content in diseased skin. The remainder
of the staining extended over the normal localization for
involucrin and filaggrin. A significantly reduced involucrin
protein content was found by western blot analysis in
lesional skin and even more pronouncedly in non-lesional
skin of AD. Involucrin serves as a substrate for the covalent
attachment of ceramides to the cornified envelope (Wertz
et al, 1986; Marekov and Steinert, 1998). Recently, it was
found that the amount of protein-bound o-hydroxycera-
mides was significantly decreased in non-lesional skin and
drastically reduced in lesional skin of AD (Macheleidt et al,
2002). According to our results, reduced involucrin content
may cause the reduced amount of o-hydroxyceramides in
AD by failing to provide a sufficient amount of substrate for
the attachment of ceramides.
In contrast to involucrin and filaggrin, loricrin expression
was significantly increased in non-lesional and lesional
epidermis of AD, as shown by western blotting. Immuno-
histology also revealed increased staining in the upper
epidermis. Though the genes for filaggrin, involucrin, and
loricrin are localized on the same gene 1q21, also known as
the epidermal differentiation complex, the loricrin gene does
not necessarily share the same regulatory elements with
the filaggrin and involucrin genes (Yoneda et al, 1992). The
reason for the increase in loricrin expression in AD is
unclear. Hohl described overexpression of loricrin and
involucrin in orthokeratotic acanthosis, such as lichen
planus. In unspecified dermatitis, however, he found
reduced loricrin expression (Hohl, 1993). The altered
expression of involucrin, filaggrin, and loricrin is in agree-
ment with recently published work on genome screening
for AD. Cookson et al found genetic linkage to AD on
chromosome 1q21 (Cookson et al, 2001).
We also found that changes in keratins occurred in AD.
Extended expression of basal keratin K 5 was already noted
in non-lesional skin and was even more pronounced in
lesional skin of AD. Previously, we have found increased K 5
immunostaining in young as well as aged dry skin (Engelke
et al, 1997). The expression of the suprabasal/differentiation
related K 10 was reduced in lesional AD only. Staining for K
10 was concentrated in the granular and upper spinous
layers, but reduced in the lower spinous layers of the
epidermis. Reduced K 10 was also noted in dry skin in our
previous studies (Engelke et al, 1997). We have also found in
previous studies that expression of differentiation marker K
10 is impaired after acute experimental barrier disruption
(Ekanayake-Mudiyanselage et al, 1998). In K 10 deficient
mice, a defect in permeability barrier function has been
found (Jensen et al, 2000). Therefore, reduced K 10 in
lesional skin of AD may be related to dry skin conditions and
to disturbed barrier function. But K 10 may not be a very
sensitive marker for these conditions, as staining in non-
lesional skin was unchanged when compared with normal
skin.
Proliferation-associated cytokeratins were expressed in
AD, a reasonable outcome with the increased proliferation
already shown above. Staining with the cytokeratins K 6
and K 16, however, produced different results. K 6 was not
expressed in healthy control and in non-lesional AD skin. In
contrast, pronounced staining in the suprabasal levels
occurred in lesional AD. While K 16 was not expressed in
healthy skin, intense staining was already noted in the
middle and upper parts of the spinous layers in non-lesional
skin. In lesional AD, intense staining in all suprabasal layers
occurred. The reason for these differences in K 6 and K 16
protein expression are unknown. The inflammation-asso-
ciated K 17 was not expressed in healthy and non-lesional
skin. In lesional skin, staining was found in all suprabasal
layers and the intensity continuously increased toward
the stratum granulosum. Clinically, redness as a sign of
inflammation is present in lesional but not in non-lesional
skin of AD.
In conclusion, our study shows that AD exhibits reduced
A- and N-SMase activities. Reduced A-SMase activity may
be partially responsible for the reduced content of stratum
corneum ceramides. Reduced N-SMase activity may lead
to changes in signal transduction, thereby regulating
differentiation. The resulting reduction in involucrin could
cause the reduced number of covalently bound ceramides
in AD. Changes in epidermal lipids and differentiation lead
to the disturbed barrier function present in AD, which
consequently allow for the entry of harmful environmental
substances into the skin, thereby triggering immunological
reactions and inflammation.
Materials and Methods
Patients Twenty-five adult patients with AD (17 male and eight
female) according to the criteria of Hanifin and Rajka, and 18 age
and sex-matched non-atopic controls (nine male and nine female)
were included in the study (Hanifin and Rajka, 1980). Skin biopsies
were obtained from lesional and non-lesional skin on the backs or
thighs of each patient. Individuals were selected for participation
when they showed a severe form of AD (mean SCORAD of 54.2
SEM 3.2 and a IgE of 6301.1 kU per L SEM 1050.7 kU per L;
SCORAD index combines objective (extent and intensity) with
subjective (loss of sleep, pruritus) parameters. In addition, skin
hydration and TEWL were also measured on patients with lesional
and non-lesional AD and healthy controls, using a Tewameter
TM210 and Corneometer (CourageþKhazaka, Germany). The
local ethical commission approved the study protocol.
Isolation of epidermal samples Five mm punch biopsies were
obtained from the backs of patients with confirmed AD, shock
frozen, and stored at 701C or fixed with 2.5% formaldehyde for
immunohistochemistry. After thawing, the samples were immedi-
ately placed epidermal-side downward onto a covered petri dish
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containing crushed ice. The skin pieces were scraped with a
scalpel blade to remove excess subcutaneous fat and immersed at
371C for 30 min. in 10 mM EDTA in Dulbecco’s phosphate-buffered
saline, calcium (Caþ )- and magnesium (Mg2þ )-free (0.16 M NaCl,
0.01 M Na2HPO4, 0.03 M KCl, 0.01 M KH2PO4, pH 7.4). Thereafter,
the epidermis was peeled away from the dermis in one piece by
gentle scraping with a scalpel blade and dried on paper towels.
Epidermal sheets were shredded into small pieces (o1 mm3) with
scissors and stored at 701C.
In vitro assay for A- and N-SMase-activity The epidermis
samples were homogenized, respectively, in buffer A (for the
A-SMase extraction: 0.2% Triton-X 100) or B (for the N-SMase
extraction 20 mM hepes, 10 mM NaF, 2 mM EDTA, 10 mM MgCl2,
30 mM p-nitrophenyl-phosphate, 100 mM NaVanadat, 10 mM
a-glycero-phosphate, 1 mM phenyl-methyl-sulfonyl-fluoride, 1 mM
PLA (pepstatin A, leupeptin, antipain), 750 mM ATP, and 0.2%
NP-40) using a glass homogenizator (Potter S, Braun, Melsungen,
Germany) on ice at 600 rpm in 400 mL. The cell debris and nuclei
were removed by low-speed centrifugation at 420  g for 10 min.
The supernatants were used for the in vitro assay as described by
Freinkel and Traczyk (1983): 20 mg protein from the supernatants
were incubated for 2 h at 371C in a reaction buffer C (250 mM
sodium acetate and 1 mM EDTA at pH 5.0) or D (20 mM hepes and
10 mM MgCl2 at pH 7.4) for A- or N-SMase (50 mg final volume),
respectively, containing 2.25 mL of N-methyl-[14C]-sphingomyelin
(0.2 mCi per mL, specific activity 56.6 mCi per Mol, Amersham,
Freiburg, Germany) as a substrate. The reaction was stopped
by adding 800 mL chloroform:methanol (2:1, vol/vol) and 250 mL
H2O. [
14C]-phosphorylcholine, product from [14C]-sphingomyelin,
was extracted from the aqueous phase, identified by thin layer
chromatography and routinely determined by liquid scintillation
counting. The results are presented as nmol per h per mg protein.
In vitro assay for sphingomyelin deacylase-activity For esti-
mating the activity of endogenous epidermal sphingomyelin-
deacylase activity, skin samples were prepared as described for
measurements of A-SMase. 20 mg protein from the supernatants
were incubated for 2 h at 371C in reaction buffer E optimal for
sphingomyelin deacylase (Murata et al, 1996; Hara et al, 2000) (250
mM sodium acetate and 20 mM CaCl2 at pH 5.0) containing 2.25
mL of N-methyl-[14C]-sphingomyelin (0.2 mCi per mL, specific
activity 56.6 mCi per Mol, Amersham) as a substrate. The reaction
was stopped by adding 800 mL chloroform: methanol (2:1, vol/vol)
and 250 mL H2O. [
14C]-lyso-sphingomyelin, products from [14C]-
sphingomyelin were extracted from the aqueous phase, identified
by thin layer chromatography. Exogenous sphingolipid ceramide
N-deacylase was purchased from Sigma (Germany), in vitro assays
were performed in buffer D optimal for A-SMase and E, containing
CaCl2 for sphingolipid ceramide N-deacylase activity. Exogenous
A-SMase (30 and 130 mU per mL) and sphingomyelin deacylase
(10 and 40 mU per mL) were assayed each either in buffer D
containing EDTA or in buffer E, containing CaCl2 (A). To determine
endogenous activity of epidermal A-SMase and epidermal sphin-
gomyelin deacylase, assays were performed either in buffer D
containing EDTA or in buffer E, containing CaCl2 (B). Radioactive
metabolites were extracted, the aqueous phases subjectes to thin
layer chromatography and [14C]-phosphorylcholine and [14C] lyso-
sphingomyelin identified by autoradiography in a FUJI S-2000
bioimager (Raytest, Germany).
Protein determination The protein content in epidermal homo-
genates was determined by the Bradford method using bovine
serum albumin as standard (BCA-protein assay) (Bradford, 1976).
Immunohistochemistry staining Skin samples were fixed in
formalin and embedded in paraffin. After deparaffination and
rehydration, 5 mm thick sections were incubated with 3% H2O2 for
5 min. to block endogenous peroxidase activity and the rinsed
sections exposed to 5  5 min. microwave irradiation (650 W)
for antigen detection according to Hazelbag et al (1995). After
blocking non-specific antibody binding by incubation with 20%
normal pig serum (DAKO, Hamburg, Germany), the primary anti-
bodies (anti-involucrin, anti-loricrin, anti-filaggrin, or anti-keratin 5,
6, 10, 16, and 17) were applied (Rosenthal et al, 1992; Hohl, 1993).
A strep-AB-complex/HRP (DAKO, Hamburg, Germany) was used
as a third antibody, followed by incubation with diaminobenzidine
as peroxidase substrate.
Epidermal proliferation assay As described for the previously
mentioned histological slides, slides were generated and incu-
bated with Ki-67 antibodies. The stained sections (one per slide)
were examined microscopically (  160) by counting the labeled
nuclei of interfollicular keratinocytes in seven microscopic fields/
sections. Labeling index in samples of patients with AD was
defined by numbers of stained cells per mm epidermal basal
membrane.
Western blotting Epidermal samples were homogenized in 400
mL homogenization buffer (H-buffer: 40 mM hepes, 150 mM KCl,
and 5 mM NaF, pH 7.4) using a glass homogenizer (Potter S, Braun,
Melsungen, Germany) on ice at 600 rpm. The samples were lyzed
with SDS-page application buffer (50 mM tris, 4 M urea, 1% SDS,
15% glycin, 0.01% bromphenolblue, and 9% mercaptoethanol, pH
6.8), and boiled for 10 min. Five to 15 mg protein in H-buffer were
separated by SDS-page using 7.5%–12.5% polyacrylamide gels,
followed by transfer to a nitrocellulose membrane sheet. The
membranes were blocked with 2% skim milk in TBST, pH 7.0. After
incubation with polyclonal rabbit-anti-human anti-loricrin or anti-
involucrin antibody (Jackson Laboratories, Bar Harbor, Maine)
the membranes were thoroughly washed with TBST and then
incubated with HRP-conjugated second antibody. After incubation
with strep-AB-complex/HRP, signals were detected using the ECL
system (Amersham). Results are 2D laser scanned and given
in arbitrary units representing density minus background. Actin
quantification served as inner control of the western blot analysis.
Statistics Statistical significance was determined using two-tailed
Student’s t-test. Each sample was measured in duplicate and the
results are presented as the mean  SEM.
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